Response to: 'Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration' by Marshall et al - Emery, Paul; Vencovský, Jiří; Ghil, Jeehoon; Kang, Jung Won (Annals of the rheumatic diseases, 2016)
Keywords: Immunoglobulin G; biosimilární léčivé přípravky; etanercept; Biosimilar Pharmaceuticals; receptory TNF; Etanercept; Arthritis, Rheumatoid; Receptors, Tumor Necrosis Factor; antirevmatika; revmatoidní artritida; imunoglobulin G; Antirheumatic Agents